跳到主要导航 跳到搜索 跳到主要内容

Predictive value of topoisomerase II alpha protein for clinicopathological characteristics and prognosis in early breast cancer

  • Yun Wu
  • , Yiqun Han
  • , Qing Li
  • , Pin Zhang
  • , Peng Yuan
  • , Yang Luo
  • , Ying Fan
  • , Shanshan Chen
  • , Ruigang Cai
  • , Qiao Li
  • , Hangcheng Xu
  • , Yan Wang
  • , Fei Ma
  • , Jiayu Wang
  • , Binghe Xu

科研成果: 期刊稿件文章同行评审

9 引用 (Scopus)

摘要

Purpose: Topoisomerase II alpha (TOP2A) has been identified as a proliferation marker, of which the most common method for detection is immunohistochemistry (IHC). However, the optimal cut-off of TOP2A expression regarding prognostic value remains controversial. This study was to identify the optimal cut-off value of TOP2A expression and its correlation with clinicopathological variables and prognosis in early stage breast cancer in China. Methods: Between January 2013 and January 2015, a total of 1084 early breast cancer patients were enrolled. The optimal cut-off of TOP2A expression was assessed using the minimum P value approach. Correlations between TOP2A expression and clinicopathological characteristics were explored by the Spearman’s correlation analysis, while the impact of TOP2A expression on disease-free survival (DFS) and overall survival (OS) was evaluated by the Kaplan–Meier methods. Univariate and multivariate Cox regression analyses were executed to identify statistically significant prognostic factors. Results: The optimal cut-off value of TOP2A was recommended as 15%. Overall, 603 (55.6%) patients were TOP2A over-expression and 481 (44.4%) patients were TOP2A low expression. TOP2A over-expression was in positive associations with a higher Ki67 index (r = 0.83, P < 0.001), HER2 positive (r = 0.26, P < 0.001), a larger tumor size (r = 0.14, P < 0.001), and a higher histologic grade (r = 0.59, P < 0.001), and in a significantly negative correlation with hormone receptor (HR) positive expression (r = − 0.40, P < 0.001) in early breast cancer. TOP2A over-expression significantly associated with worse DFS (P = 0.001) and OS (P < 0.001) and was an independent prognostic factor for both DFS (hazard ratio [HR] = 2.04; 95% confidence interval [95% CI] 1.30–3.18, P = 0.0018) and OS (HR = 3.54; 95%CI 1.53–8.23, P = 0.003) in stage I-II breast cancer patients. Conclusion: To our knowledge, this is the first study to recommend the optimal cut-off value of TOP2A expression in breast cancer. The TOP2A expression is significantly correlated with HER2 status, Ki67 index, tumor size, histologic grade and HR status, and could be a surrogate indicator for poor prognosis of early breast cancer.

源语言英语
页(从-至)381-392
页数12
期刊Breast Cancer Research and Treatment
193
2
DOI
出版状态已出版 - 6月 2022

联合国可持续发展目标

此成果有助于实现下列可持续发展目标:

  1. 可持续发展目标 3 - 良好健康与福祉
    可持续发展目标 3 良好健康与福祉

学术指纹

探究 'Predictive value of topoisomerase II alpha protein for clinicopathological characteristics and prognosis in early breast cancer' 的科研主题。它们共同构成独一无二的指纹。

引用此